Pharmaceutical companies|Orion’s share price after the announcement was about 5 % on the Helsinki Stock Exchange.
Pharmaceutical company Orion’s operating profit increased by over 50 percent last year and was approximately EUR 417 million. The company’s net sales increased by almost 30 percent to approximately EUR 1.54 billion.
Managing director Liisa Hurme According to the stock exchange release, Orion has now achieved his long -term turnover target.
“Thanks to a strong year, we achieved our ambitious goal of Etupine in 2019 to reach a turnover of EUR 1.5 billion by the end of 2025,” Hurme says.
In the market, Orion’s earnings news was welcomed. The company’s share price was more than six percent on the Helsinki Stock Exchange in the early afternoon.
Orionin Last year’s growth was spanned by Nubeqa for treatment of prostate cancer. Hurme says that the sale of the drug during the calendar year exceeded a billion euro limit in September. The Easyhaler products for asthma treatment were also strongly successful throughout the year.
Hurme says that Orion clarified his strategy at the beginning of last year and the company’s businesses developed accordingly.
“For example, the long -standing gradient geographical blanket of Orion continued as we opened our own sales office in Japan,” Hurme says.
The company expects the year’s turnover to reach EUR 1.55-1.65 billion. As an operating profit, the company estimates EUR 350-450 million.
Orion’s Board of Directors proposes to the Annual General Meeting that a dividend of EUR 1.64 per share should be distributed in two installments. According to the government’s view, Orion’s liquidity is good and the proposed distribution of profits does not endanger the company’s solvency.